ETFs Protalix BioTherapeutics, Inc.

PLX

US74365A3095

Pharmaceuticals

Market Closed - NYSE 16:00:00 2026-11-04 EST			5-day change	1st Jan Change
2.690 ^USD	+3.07%		+3.86%	+49.44%

09-16	Protalix BioTherapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 01:05 PM
08-12	Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026

ETFs positioned on Protalix BioTherapeutics, Inc.

Name	YTD change	Weight	AuM
ISHARES MICRO-CAP ETF - USD	+14.05%	0.03%	1,518 M€
FRANKLIN U.S. SMALL CAP MULTIFACTOR INDEX ETF - USD	+16.36%	0.02%	53 M€
VANGUARD RUSSELL 2000 GROWTH ETF - USD	+10.31%	0.01%	1,568 M€
XTRACKERS RUSSELL 2000 UCITS ETF 1C - USD	+18.76%	0.01%	3,050 M€
ISHARES RUSSELL 2000 GROWTH ETF - USD	+10.44%	0.01%	15,028 M€
GLOBAL X RUSSELL 2000 ETF (AU) - AUD	+9.98%	0.01%	18 M€
ISHARES U.S. SMALL CAP INDEX ETF (CAD-HEDGED) - CAD	+13.63%	0.01%	520 M€
ISHARES RUSSELL 2000 VALUE ETF - USD	+20.66%	0.01%	14,676 M€
GLOBAL X RUSSELL 2000 COVERED CALL & GROWTH ETF - USD	+6.76%	0%	9 M€
GLOBAL X RUSSELL 2000 ETF - USD	+15.23%	0%	1,540 M€
ISHARES RUSSELL 2000 ETF - USD	+15.38%	0%	82,179 M€
GLOBAL X RUSSELL 2000 COVERED CALL ETF - USD	+0.85%	0%	1,395 M€
VANGUARD RUSSELL 3000 ETF - USD	+12.46%	0%	4,863 M€
UNLIMITED HFEQ EQUITY LONG/SHORT ETF - USD	+10.06%	0%	19 M€
ISHARES LIFEPATH TARGET DATE 2065 ETF - USD	+12.90%	0%	29 M€
ISHARES LIFEPATH TARGET DATE 2055 ETF - USD	+12.82%	0%	60 M€
ISHARES LIFEPATH TARGET DATE 2060 ETF - USD	+13.07%	0%	41 M€
UNLIMITED HFGM GLOBAL MACRO ETF - USD	+1.56%	0%	162 M€
ISHARES LIFEPATH TARGET DATE 2050 ETF - USD	+12.35%	0%	88 M€
CI GLOBAL CORE PLUS EQUITY ETF - CAD	0.00%	0%	43 M€
ISHARES LIFEPATH TARGET DATE 2045 ETF - USD	+11.18%	0%	91 M€
ISHARES LIFEPATH TARGET DATE 2070 ETF - USD	+12.89%	0%	16 M€
ISHARES LIFEPATH TARGET DATE 2040 ETF - USD	+9.97%	0%	110 M€
ISHARES LIFEPATH TARGET DATE 2035 ETF - USD	+8.34%	0%	113 M€
SIMPLIFY PIPER SANDLER US SMALL-CAP PLUS INCOME ETF - USD	+17.83%	0%	7 M€
BRIDGES CAPITAL TACTICAL ETF - USD	+5.27%	0%	43 M€
CAMBRIA US EW ETF - USD	+11.53%	0%	194 M€
WARREN STREET GLOBAL EQUITY ETF - USD	+13.53%	0%	62 M€
ALPHA ARCHITECT US EQUITY 2 ETF - USD	+10.73%	0%	513 M€
INFRACAP SMALL CAP INCOME ETF - USD	-1.75%	0%	20 M€
SIMPLIFY VOLATILITY PREMIUM ETF - USD	-9.45%	-.--%	538 M€

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.

Employees

226

Sector

Pharmaceuticals

Calendar

11-10 Earnings release - Q3 2026

More about the company